Bushen Daozhuo Granules for type Ⅲ prostatitis: A multicenter randomized controlled clinical trial / 中华男科学杂志
National Journal of Andrology
;
(12): 164-168, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-812792
ABSTRACT
Objective@#To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis.@*METHODS@#This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients.@*RESULTS@#Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P 0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05).@*CONCLUSIONS@#BDG is safe and effective for the treatment of type Ⅲ prostatitis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Prostatitis
/
Sulfonamides
/
Capsules
/
Drugs, Chinese Herbal
/
Chronic Disease
/
Treatment Outcome
/
Delayed-Action Preparations
/
Therapeutic Uses
/
Drug Therapy
Type of study:
Controlled clinical trial
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS